News
![Is Invitae Stock a Buy Now?: https://g.foolcdn.com/editorial/images/762971/gettyimages-1072035598.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOWdaYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--d047e303694c7149834d61f7b565ac195e70ee2b/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-1072035598.jpg?locale=us)
Is Invitae Stock a Buy Now?
Invitae (NYSE: NVTA) has grown revenue over time, but the genetic testing specialist has failed to turn that into profit. Instead, the company burned through more and more cash, prompting it to
![A Bull Market Is Here: 2 Stocks to Buy and Hold for 10 Years: https://g.foolcdn.com/editorial/images/762335/patient-taking-medicine.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNVFaYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--81780a59b9fb4ab74433f1f8a4382d774df170d0/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/patient-taking-medicine.jpg?locale=us)
A Bull Market Is Here: 2 Stocks to Buy and Hold for 10 Years
With the S&P 500 index recently hitting a new all-time high, we can officially declare that we are in a bull market. While that's exciting news, it doesn't change the blueprint of success for
![2 Under-the-Radar Stocks With Incredible Upside Potential: https://g.foolcdn.com/editorial/images/762022/physician-shaking-patients-hand.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNGdaYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--037a688041aaff92c0fa65628ae48f1cf8a3c5df/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/physician-shaking-patients-hand.jpg?locale=us)
2 Under-the-Radar Stocks With Incredible Upside Potential
What's the appeal of investing in relatively small and little-known corporations? Though these businesses come with heightened risks, getting in on the ground floor can potentially be lucrative over
![1 Reason to Buy Novavax Stock Hand Over Fist and 1 Reason to Sell: https://g.foolcdn.com/editorial/images/762839/gettyimages-1295986889.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMzBaYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--d42687042adb76d33226786fe86b98d63b729ea4/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-1295986889.jpg?locale=us)
1 Reason to Buy Novavax Stock Hand Over Fist and 1 Reason to Sell
Novavax (NASDAQ: NVAX) shares have offered investors a roller coaster ride over the past few years. They soared more than 2,700% in early pandemic days as investors bet on the company's
![AT&T's Fiber Investment Is Turning Into a Home Run: https://g.foolcdn.com/editorial/images/762742/gettyimages-1251503688.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMzRaYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--74e881c79308616e441c4bd70e6225e23ca5bba7/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-1251503688.jpg?locale=us)
AT&T's Fiber Investment Is Turning Into a Home Run
While the wireless business is the largest contributor to AT&T's (NYSE: T) revenue by far, the fiber internet business is proving to be a potent growth opportunity. Capturing that growth comes at a
![Where Will Pfizer Be in 10 Years?: https://g.foolcdn.com/editorial/images/762485/scientists-work-in-lab-smiling.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMk1aYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a3c56b0bf8e7305f831a84f879666e47034383ef/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/scientists-work-in-lab-smiling.jpg?locale=us)
Where Will Pfizer Be in 10 Years?
Pfizer (NYSE: PFE) has reached a major transition point. The big pharma company took center stage earlier in the COVID-19 pandemic when it became the first to launch a coronavirus vaccine. That
![Is It Too Late to Buy Novavax Stock?: https://g.foolcdn.com/editorial/images/762426/doctor-vaccinating-a-patient.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMUFaYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9bb297630a896e1553721da96c4bfb2c48325e09/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/doctor-vaccinating-a-patient.jpg?locale=us)
Is It Too Late to Buy Novavax Stock?
A few years ago, biotech company Novavax (NASDAQ: NVAX) looked like a promising stock. It emerged as a leader in the development of a COVID-19 vaccine, which sent its share price through the roof.
![Here's My Top Growth Stock to Buy Right Now: https://g.foolcdn.com/editorial/images/762404/scientist-monitors-with-dna.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeThaYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e548e5df4c40d91f842bacfe2a024a139205f08d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/scientist-monitors-with-dna.jpg?locale=us)
Here's My Top Growth Stock to Buy Right Now
I'll readily admit that I've picked some supposed growth stocks in the past that didn't deliver much growth. The good news, though, is that my winners have far outpaced my losers over the long run.
![Amgen's Planning to Take a Bite Out of Cancer. Here's What It Means for the Stock.: https://g.foolcdn.com/editorial/images/761951/chemist-team-looking-beaker-of-green-chemical.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeVlaYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9bf7ee2bce60a882e95bb8f5756d8a68ca3d9172/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/chemist-team-looking-beaker-of-green-chemical.jpg?locale=us)
Amgen's Planning to Take a Bite Out of Cancer. Here's What It Means for the Stock.
Cancer bites, but Amgen (NASDAQ: AMGN) is going to keep biting back. In fact, it's currently developing a handful of oncology medicines that it describes as bispecific T-cell engager therapies, or
![Is It Too Late to Buy Intellia Therapeutics Stock?: https://g.foolcdn.com/editorial/images/761917/elderly-person-sitting-on-a-bed.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeEFaYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--90c75900a31f039932f419d81f3949c5ec26a89f/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/elderly-person-sitting-on-a-bed.jpg?locale=us)
Is It Too Late to Buy Intellia Therapeutics Stock?
Companies focusing on developing gene editing therapies have made significant progress over the past year. However, that has done little to keep Intellia Therapeutics (NASDAQ: NTLA) afloat. The
![Where Will Novavax Be in 5 Years?: https://g.foolcdn.com/editorial/images/762089/a-person-receiving-a-vaccine-from-a-nurse.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeEVaYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--04c9412838457a94ddd6045a801a99bccfce7e91/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-person-receiving-a-vaccine-from-a-nurse.jpg?locale=us)
Where Will Novavax Be in 5 Years?
There was a lot of promise around Novavax (NASDAQ: NVAX) and its COVID vaccine a few years ago. But with the company being late to the finish line and now generating limited revenue from the
![3 Magnificent Stocks to Buy and Hold Forever: https://g.foolcdn.com/editorial/images/762671/hands-behind-head-young-man.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL2dZYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--c1259d4cca596631431422ac4fbe807b13a15f3b/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/hands-behind-head-young-man.jpg?locale=us)
3 Magnificent Stocks to Buy and Hold Forever
Time in the market beats timing the market, hands-down. But how long should you own a stock?
Famed investor Warren Buffett perhaps said it best: "When we own portions of outstanding businesses with
![AT&T Is Still a No-Brainer Value Stock to Buy in 2024: https://g.foolcdn.com/editorial/images/762664/telecom-worker-woman-industrials-5g-tech-12.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK1lZYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3cf3284285404e7088cdf2059566e563fbfacae1/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/telecom-worker-woman-industrials-5g-tech-12.jpg?locale=us)
AT&T Is Still a No-Brainer Value Stock to Buy in 2024
Shares of telecom giant AT&T (NYSE: T) headed lower last Wednesday following a fourth-quarter report that was a bit less positive than investors may have been expecting. Overall, the company's
![Is It Finally Safe to Buy AT&T Stock?: https://g.foolcdn.com/editorial/images/762549/t_sankey_q42023.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeEVZYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--aa250381f4df5bff26662ecc1bc452aa3001a989/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/t_sankey_q42023.png?locale=us)
Is It Finally Safe to Buy AT&T Stock?
It's not often that a stock hits a 30-year low, but AT&T (NYSE: T) did just that last summer in the wake of revelations that "toxic" lead-clad cables left behind underground and underwater by the
![AT&T Earnings: Everything You Need to Know: https://g.foolcdn.com/editorial/images/762499/telecom-network-city.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK2NYYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--8d9bd914ce5777309cc52fff0437f6a23fd09e85/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/telecom-network-city.jpg?locale=us)
AT&T Earnings: Everything You Need to Know
AT&T's (NYSE: T) shares fell after earnings, but there were some positive signs for the telecom company. Travis Hoium covers the report, and where there were strengths and weaknesses, in this video.
![Why AT&T Stock Topped the Market Today: https://g.foolcdn.com/editorial/images/762743/person-looking-pleased-while-gazing-at-a-smartphone.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBODBYYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--2888ac749df3be2f38bda2c1796d1b50f5320ec7/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/person-looking-pleased-while-gazing-at-a-smartphone.jpg?locale=us)
Why AT&T Stock Topped the Market Today
One day after reporting fourth-quarter figures that disappointed many investors, AT&T (NYSE: T) stock bounced back nicely on Thursday. Buoyed by several analyst price target increases, the sturdy
![Where Will Vertex Pharmaceuticals Be in 10 Years?: https://g.foolcdn.com/editorial/images/761896/person-sitting-and-working-at-a-desk.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMzhYYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9f351a174ee9c6a921e67ef2bdd2bf6a9d180ba2/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/person-sitting-and-working-at-a-desk.jpg?locale=us)
Where Will Vertex Pharmaceuticals Be in 10 Years?
Those who put money in Vertex Pharmaceuticals (NASDAQ: VRTX) 10 years ago are sitting pretty right now. The company has easily outpaced the market over this period.
However, a lot has changed for
![Could Sarepta Therapeutics Become the Next Vertex Pharmaceuticals?: https://g.foolcdn.com/editorial/images/761906/person-working-at-a-desk.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMGtYYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--969bec97c09a0fc3e5e73b30b14d2dcc4e6c4d89/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/person-working-at-a-desk.jpg?locale=us)
Could Sarepta Therapeutics Become the Next Vertex Pharmaceuticals?
Sarepta Therapeutics (NASDAQ: SRPT) and Vertex Pharmaceuticals (NASDAQ: VRTX) have a lot in common: Both operate in the tricky biotech industry, and both seek to develop treatments primarily for
![How Does Pfizer Fit Into a Well-Diversified Portfolio?: https://g.foolcdn.com/editorial/images/762494/confused.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBODBXYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--4a1fc9939df572a4c3870ba04dfb81f627a24ea1/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/confused.jpg?locale=us)
How Does Pfizer Fit Into a Well-Diversified Portfolio?
Building a balanced portfolio requires careful planning and execution. You need to think about your long-term objectives for growth and income, as well as tax implications, when you need to adjust
![2 No-Brainer Dividend Stocks to Buy for the New Year: https://g.foolcdn.com/editorial/images/762006/getty-happy-couple-reassured-relief-relieved.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNlFXYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a2305d78078892d570842960ed418776195a97ce/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/getty-happy-couple-reassured-relief-relieved.jpg?locale=us)
2 No-Brainer Dividend Stocks to Buy for the New Year
As you build your portfolio through the years, you may find that you gravitate toward stocks across an assortment of sectors, with a range of risk profiles, growth stories, and businesses
![AT&T Stock Fell After Its Q4 Release Today -- Time to Buy This High-Yield, Passive Income Machine Hand Over Fist?: https://g.foolcdn.com/editorial/images/762568/hundred-dollar-bill-with-chart-arrow-moving-up.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMWNXYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--da0ebef03eb5ecc4996ef41e3b4993210f9b88e1/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/hundred-dollar-bill-with-chart-arrow-moving-up.jpg?locale=us)
AT&T Stock Fell After Its Q4 Release Today -- Time to Buy This High-Yield, Passive Income Machine Hand Over Fist?
AT&T (NYSE: T) stock lost ground in Wednesday's daily trading. The telecom company's share price closed out the session down 3%, according to data from S&P Global Market Intelligence.
AT&T published
![AT&T; (T) Q4 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeSt3V1E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9dfca4603c1fc3af5c96a68f8938e1fa8ce6aed8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/featured-transcript-logo-template-2023-01-12.jpg?locale=us)
AT&T; (T) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
AT&T (NYSE: T)Q4 2023 Earnings CallJan 24, 2024, 8:30 a.m. ET
Operator
Source Fool.com
![Abbott Laboratories (ABT) Q4 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeSt3V1E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9dfca4603c1fc3af5c96a68f8938e1fa8ce6aed8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/featured-transcript-logo-template-2023-01-12.jpg?locale=us)
Abbott Laboratories (ABT) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
Abbott Laboratories (NYSE: ABT)Q4 2023 Earnings CallJan 24, 2024, 9:00 a.m. ET
Operator
Source Fool.com
![Why AT&T Stock Was Sliding Today: https://g.foolcdn.com/editorial/images/762493/att-5g.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeHdXYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--97388138828232c5e38cff31d308bd16f54442ed/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/att-5g.jpg?locale=us)
Why AT&T Stock Was Sliding Today
Shares of AT&T (NYSE: T) were falling today after strong phone subscriber additions were overshadowed by weak guidance for the new year.
After gaining yesterday in sympathy with a
![Where Will CRISPR Therapeutics Be in 5 Years?: https://g.foolcdn.com/editorial/images/761459/patient-sitting-on-hospital-bed.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK0VWYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--b2162bf0b8dc6c5313811890805f10fe05a54a77/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/patient-sitting-on-hospital-bed.jpg?locale=us)
Where Will CRISPR Therapeutics Be in 5 Years?
It finally happened. About 10 years after being created, gene-editing specialist CRISPR Therapeutics (NASDAQ: CRSP) earned approval for its first therapy late last year. The treatment in question is